Nektar Therapeutics (NKTR) Misses Q4 EPS by 3c

Nektar Therapeutics (NASDAQ: NKTR) reported Q4 EPS of ($0.57), $0.03 worse than the analyst estimate of ($0.54). Revenue for the quarter came in at $39.8 million versus the consensus estimate of $45.92 million.

For earnings history and earnings-related data on Nektar Therapeutics (NKTR) click here.

You May Also Be Interested In

• After-Hours Movers: WDAY, ADSK, S, RBRK, MRVL, ULTA, GAP, AFRM
• PagerDuty, Inc. (PD) Tops Q2 EPS by 1c; offers guidance
• SolarEdge (SEDG) PT Lowered to $31 at Jefferies, 'We see shares as an unappealing short, not a compelling long'